Cargando…

A new day, a new treatment. A case report

INTRODUCTION: We present the case of a 21 year-old male, with history of a psychotic episode, currently with monthly follow-up in an outpatient facility, with a favorable clinical evolution after one year of intensive follow-up. In the context of abandonment of his medication and a problematic famil...

Descripción completa

Detalles Bibliográficos
Autores principales: Galerón, R., Serván, B., Huete Naval, M., Herrero Pellón, E., Albarracin, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568230/
http://dx.doi.org/10.1192/j.eurpsy.2022.1870
_version_ 1784809596581314560
author Galerón, R.
Serván, B.
Huete Naval, M.
Herrero Pellón, E.
Albarracin, P.
author_facet Galerón, R.
Serván, B.
Huete Naval, M.
Herrero Pellón, E.
Albarracin, P.
author_sort Galerón, R.
collection PubMed
description INTRODUCTION: We present the case of a 21 year-old male, with history of a psychotic episode, currently with monthly follow-up in an outpatient facility, with a favorable clinical evolution after one year of intensive follow-up. In the context of abandonment of his medication and a problematic family situation, the patient starts to show suspicious, with insomnia and a progressive social isolation. Despite an attempt of ambulatory treatment with oral aripiprazole, showing good tolerance, the patient refuses such treatment, showing active clinical psychotic with great distress and behavioral repercussion, finally requiring hospital admission. OBJECTIVES: To perform a literature review about the treatment initiation with two vials of aripiprazole long-acting injection. METHODS: Literature review of scientific articles using Pubmed as search engine. We considered articles published both in English and Spanish. RESULTS: During hospital stay, treatment with 2 intramuscular injections of 400mg of aripiprazole is started, combined with a single dose of oral aripiprazole 20mg on day 1, assuring correct dosing, with good tolerance and favoring therapeutic adherence. Progressively, the patient starts to feel calmer, adequate, collaborative and emotionally stable, recuperating chronobiological rhythms, with remission of the hallucinations and appearing more distant from delusions. CONCLUSIONS: According to the currently available studies, the use of this posology could avoid the potential impact that lack of adherence to oral treatment could have in the therapeutic outcome, assuring a correct dosing and favoring adherence from day 1. Furthermore, this would help simplify the medication regiment for patients, physicians and caregivers. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9568230
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95682302022-10-17 A new day, a new treatment. A case report Galerón, R. Serván, B. Huete Naval, M. Herrero Pellón, E. Albarracin, P. Eur Psychiatry Abstract INTRODUCTION: We present the case of a 21 year-old male, with history of a psychotic episode, currently with monthly follow-up in an outpatient facility, with a favorable clinical evolution after one year of intensive follow-up. In the context of abandonment of his medication and a problematic family situation, the patient starts to show suspicious, with insomnia and a progressive social isolation. Despite an attempt of ambulatory treatment with oral aripiprazole, showing good tolerance, the patient refuses such treatment, showing active clinical psychotic with great distress and behavioral repercussion, finally requiring hospital admission. OBJECTIVES: To perform a literature review about the treatment initiation with two vials of aripiprazole long-acting injection. METHODS: Literature review of scientific articles using Pubmed as search engine. We considered articles published both in English and Spanish. RESULTS: During hospital stay, treatment with 2 intramuscular injections of 400mg of aripiprazole is started, combined with a single dose of oral aripiprazole 20mg on day 1, assuring correct dosing, with good tolerance and favoring therapeutic adherence. Progressively, the patient starts to feel calmer, adequate, collaborative and emotionally stable, recuperating chronobiological rhythms, with remission of the hallucinations and appearing more distant from delusions. CONCLUSIONS: According to the currently available studies, the use of this posology could avoid the potential impact that lack of adherence to oral treatment could have in the therapeutic outcome, assuring a correct dosing and favoring adherence from day 1. Furthermore, this would help simplify the medication regiment for patients, physicians and caregivers. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9568230/ http://dx.doi.org/10.1192/j.eurpsy.2022.1870 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Galerón, R.
Serván, B.
Huete Naval, M.
Herrero Pellón, E.
Albarracin, P.
A new day, a new treatment. A case report
title A new day, a new treatment. A case report
title_full A new day, a new treatment. A case report
title_fullStr A new day, a new treatment. A case report
title_full_unstemmed A new day, a new treatment. A case report
title_short A new day, a new treatment. A case report
title_sort new day, a new treatment. a case report
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568230/
http://dx.doi.org/10.1192/j.eurpsy.2022.1870
work_keys_str_mv AT galeronr anewdayanewtreatmentacasereport
AT servanb anewdayanewtreatmentacasereport
AT huetenavalm anewdayanewtreatmentacasereport
AT herreropellone anewdayanewtreatmentacasereport
AT albarracinp anewdayanewtreatmentacasereport
AT galeronr newdayanewtreatmentacasereport
AT servanb newdayanewtreatmentacasereport
AT huetenavalm newdayanewtreatmentacasereport
AT herreropellone newdayanewtreatmentacasereport
AT albarracinp newdayanewtreatmentacasereport